Art. 2 Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…

Scope

In forcesince 6 May 2009cited 28×

Any product protected by a patent in the territory of a Member State and subject, prior to being placed on the market as a medicinal product, to an administrative authorisation procedure as laid down in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [OJ L 311, 28.11.2001, p. 67.] or Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products [OJ L 311, 28.11.2001, p. 1.] may, under the terms and conditions provided for in this Regulation, be the subject of a certificate.

The 10 that are cited most themselves, of 28.

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision

    Article 2 of Regulation No 469/2009, entitled ‘Scope’, is worded as follows: ‘Any product protected by a patent in the territory of a Member State and subject, prior to being placed on the market as a medicinal product, to an …

    24 Nov 2011 · 62010CJ0322

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Georgetown University and Others v Comptroller General of Patents, Designs and TDecision

    Moreover, as is apparent in particular from subparagraphs 4 and 5 of paragraph 28 of the explanatory memorandum to the proposal for Council Regulation (EEC) of 11 April 1990 concerning the creation of a supplementary protection certificate …

    24 Nov 2011 · 62010CJ0422

  • Judgment of the Court (Eighth Chamber) of 15 January 2015. Arne Forsgren v Österreichisches Patentamt.Decision

    Article 2 of Regulation No 469/2009 provides that any product protected by a patent in the territory of a Member State and subject, prior to being placed on the market as a medicinal product, to an administrative authorisation procedure, …

    15 Jan 2015 · 62013CJ0631

  • Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decision

    As is apparent from the respective headings of Articles 2 and 3 of the SPC Regulation, namely, ‘Scope’ and ‘Conditions for obtaining [an SPC]’, first, Article 2 of that regulation seeks to determine in a general manner which …

    19 Jul 2012 · 62011CJ0130

  • Order of the Court (Fourth Chamber) of 25 November 2011. University of Queensland and CSL Ltd v Comptroller General of Patents, Designs and Decision

    It is sufficient to point out that a patent protecting the process by which a ‘product’ within the meaning of Regulation No 469/2009 is obtained may, in accordance with Article 2 of the regulation, enable a SPC to be granted and, in …

    25 Nov 2011 · 62010CO0630

  • Order of the Court (Fourth Chamber) of 25 November 2011. Daiichi Sankyo Company v Comptroller General of Patents, Designs and Trade Marks.Decision

    Article 2 of Regulation No 469/2009, entitled ‘Scope’, is worded as follows: ‘Any product protected by a patent in the territory of a Member State and subject, prior to being placed on the market as a medicinal product, to an …

    25 Nov 2011 · 62011CO0006

  • Order of the Court (Eighth Chamber), 14 November 2013. Glaxosmithkline Biologicals SA and Glaxosmithkline Biologicals, Niederlassung der SmiDecision

    This reference for a preliminary ruling concerns the interpretation of Article 1(b) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for …

    14 Nov 2013 · 62013CO0210

  • Judgment of the Court (Fourth Chamber) of 21 March 2019. Abraxis Bioscience LLC v Comptroller General of Patents.Decision

    Article 2 of that regulation provides: ‘Any product protected by a patent in the territory of a Member State and subject, prior to being placed on the market as a medicinal product, to an administrative authorisation procedure as laid …

    21 Mar 2019 · 62017CJ0443

  • Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision

    Article 2 of that regulation provides as follows: ‘Any product protected by a patent in the territory of a Member State and subject, prior to being placed on the market as a medicinal product, to an administrative authorisation procedure …

    9 Jul 2020 · 62018CJ0673

  • Joined opinion of Advocate General Trstenjak delivered on 13 July 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision

    Articles 1 to 7 of Regulation No 469/2009 read as follows: ‘Article 1 — Definitions For the purposes of this Regulation: “medicinal product” means any substance or combination of substances presented for treating or preventing …

    13 Jul 2011 · 62010CC0322